Voydeya has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, announced AstraZeneca. “It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris or Soliris to address the needs of the subset of approximately 10-20% patients with PNH who experience clinically significant extravascular haemolysis while treated with a C5 inhibitor,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca price target raised to 13,400 GBp from 12,900 GBp at Morgan Stanley
- AstraZeneca downgraded to Sell from Buy at UBS
- AIM ImmunoTech announces open enrollment for Phase 1b/2 study of Ampligen
- Absci appoints Sir Pangalos to its board of directors
- AstraZeneca put volume heavy and directionally bearish